Flourish Research Acquisition LLC — research payments reported

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$14,582,477	55
2024	Research	$3,028,674	22

Breakdown

Who paid Research payments · program years 2024–2025

Eli Lilly and Company $17,433,450 71 payments
Amgen Inc. $138,532 3 payments
Pfizer Inc. $27,995 2 payments
Novartis Pharmaceuticals Corporation $11,175 1 payment

Studies the money was for Research payments · program years 2024–2025

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone Or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity Or Overweight Without Type 2 Diabetes $5,773,211 7 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $4,530,170 12 payments
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $2,403,792 15 payments
A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $2,129,196 12 payments
A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity Or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (Attain-Hypertension). Isas-Gzl1;Gzl2 $1,031,120 3 payments
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity $811,896 2 payments
A Phase 2, Parallel-Group, Double-Blind Study to Investigate the Safety and Tolerability of Ly3549492 Compared With Placebo in Adult Participants 55 to 80 Years of Age and Bmi Within 22 to 25 Kg/M2 $144,447 3 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Psa) $140,773 3 payments
A Study of Retatrutide (Ly3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity Or Overweight (Triumph-2) $129,382 4 payments
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $124,600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.